Jazz Pharmaceuticals (JAZZ) Competitors

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.

Which has more risk and volatility, RPRX or JAZZ?

Royalty Pharma has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Does the MarketBeat Community favor RPRX or JAZZ?

Jazz Pharmaceuticals received 818 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.86% of users gave Jazz Pharmaceuticals an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 327 67.98%	Underperform Votes 154 32.02%
Jazz Pharmaceuticals	Outperform Votes 1145 80.86%	Underperform Votes 271 19.14%

Which has stronger earnings & valuation, RPRX or JAZZ?

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.26B	8.76	$858.98M	$1.85	19.06
Jazz Pharmaceuticals	$4.06B	1.67	$414.83M	$7.50	14.71

Do analysts rate RPRX or JAZZ?

Royalty Pharma presently has a consensus target price of $47.33, indicating a potential upside of 34.20%. Jazz Pharmaceuticals has a consensus target price of $184.00, indicating a potential upside of 66.83%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Is RPRX or JAZZ more profitable?

Royalty Pharma has a net margin of 37.94% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	37.94%	24.40%	14.01%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Does the media prefer RPRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 9 more articles in the media than Royalty Pharma. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 7 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 0.97 beat Royalty Pharma's score of 0.85 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in RPRX or JAZZ?

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 10 of the 19 factors compared between the two stocks.